Patents by Inventor Kazuo Kitamura
Kazuo Kitamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12093807Abstract: A neural network not requiring massive changes in configuration when changing the number of stages (number of levels) of the neural network. This neural network is provided with at least one neuron core 10 performing an analog multiply-accumulate operation and a weight-value-supply control unit 30 supplying the weight value to the neuron core 10. This neural network is subjected to control processing by a control-processor unit 40 controlling the supply of the weight value from said weight-value-supply control unit 30 in synchronization with the timing of the analog multiply-accumulate operation of the neuron core 10, and processing the data output from the neuron core 10 at every analog multiply-accumulate operation performed by said neuron core as serial data and/or parallel data.Type: GrantFiled: June 3, 2020Date of Patent: September 17, 2024Assignees: Kabushikiki Kaisha Toshiba, Toshiba Information Systems (Japan) CorporationInventors: Takao Marukame, Kazuo Ishikawa, Junichi Sugino, Toshimitsu Kitamura, Yutaka Tamura, Koji Takahashi
-
Publication number: 20230321196Abstract: The present invention provides a means for preventing and/or treating a symptom of a viral infection in a subject affected by the viral infection without inducing any undesired serious side effect by optimizing the application method and the dose of a medicine containing AM or a derivative thereof as an active ingredient. One aspect of the present invention relates to a medicine for preventing or treating a symptom or disorder in a subject affected by a viral infection, the medicine containing adrenomedullin or a derivative thereof as an active ingredient.Type: ApplicationFiled: September 8, 2021Publication date: October 12, 2023Applicant: University of MiyazakiInventors: Kazuo Kitamura, Toshihiro Kita
-
Publication number: 20230174607Abstract: The invention provides novel adrenomedullin analogs that exhibit high biological stability in administering to subjects while maintaining pharmacological effects of the parent compound adrenomedullin.Type: ApplicationFiled: April 2, 2021Publication date: June 8, 2023Applicant: University of MiyazakiInventor: Kazuo Kitamura
-
Publication number: 20230142095Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: October 4, 2022Publication date: May 11, 2023Applicant: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki
-
Publication number: 20230120030Abstract: There is provided a novel adrenomedullin derivative capable of sustainably acting for a longer period than natural adrenomedullin. The invention relates to a compound represented by formula (I): A-Ln-B (I), wherein A is a modifying group selected from the group consisting of a palmitoyl group and a polyethylene glycol group, L is a divalent linking group, n is an integer of 0 or 1, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is bound to the modifying group A or the linking group L via the N-terminal amino group of the peptide moiety B, or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: July 29, 2022Publication date: April 20, 2023Applicant: University of MiyazakiInventors: Kazuo Kitamura, Johji Kato, Keishi Kubo, Kenji Kuwasako, Shigeru Kubo, Kumiko Kumagaye
-
Patent number: 11578112Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. An aspect of the invention relates to a compound represented by formula (I): [wherein A is an Fc region of an immunoglobulin, B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, and L is a linking group comprising a peptide having any given amino acid sequence] or a salt thereof, or a hydrate thereof. Another aspect of the invention relates to a method for producing the compound represented by formula (I), and a medicament comprising the compound as an active ingredient. A-L-B??(I).Type: GrantFiled: March 29, 2018Date of Patent: February 14, 2023Assignee: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki, Sayaka Nagata
-
Patent number: 11478551Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2-B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: GrantFiled: September 29, 2020Date of Patent: October 25, 2022Assignee: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki
-
Patent number: 11414474Abstract: There is provided a novel adrenomedullin derivative capable of sustainably acting for a longer period than natural adrenomedullin. The invention relates to a compound represented by formula (I): A-Ln-B (I), wherein A is a modifying group selected from the group consisting of a palmitoyl group and a polyethylene glycol group, L is a divalent linking group, n is an integer of 0 or 1, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is bound to the modifying group A or the linking group L via the N-terminal amino group of the peptide moiety B, or a salt thereof, or a hydrate thereof.Type: GrantFiled: March 20, 2015Date of Patent: August 16, 2022Assignee: University of MiyazakiInventors: Kazuo Kitamura, Johji Kato, Keishi Kubo, Kenji Kuwasako, Shigeru Kubo, Kumiko Kumagaye
-
Patent number: 11382498Abstract: An ophthalmologic apparatus includes a measurement optical system to acquire information of an eye, an image obtaining part to obtain an anterior ocular segment image of the eye on an optical axis of the measurement optical system, a display to display the anterior ocular segment image, cameras to each capture an image of an anterior ocular segment of the eye from a different direction, a driving mechanism to move the measurement optical system in a vertical direction and a horizontal direction, and a controller. The controller is configured to acquire three-dimensional position information of the eye based on the images captured by the cameras and calculate moving amounts in the vertical and horizontal directions of the measurement optical system based on the three-dimensional position information. The controller is configured to display the anterior ocular segment image on the display while positioning the measurement optical system with the driving mechanism.Type: GrantFiled: June 11, 2019Date of Patent: July 12, 2022Assignee: TOPCON CORPORATIONInventor: Kazuo Kitamura
-
Publication number: 20210115103Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. An aspect of the invention relates to a compound represented by formula (I): [wherein A is an Fc region of an immunoglobulin, B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, and L is a linking group comprising a peptide having any given amino acid sequence] or a salt thereof, or a hydrate thereof. Another aspect of the invention relates to a method for producing the compound represented by formula (I), and a medicament comprising the compound as an active ingredient.Type: ApplicationFiled: March 29, 2018Publication date: April 22, 2021Applicant: UNIVERSITY OF MIYAZAKIInventors: Kazuo KITAMURA, Motoo YAMASAKI, Sayaka NAGATA
-
Publication number: 20210008219Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2-B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: September 29, 2020Publication date: January 14, 2021Applicant: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki
-
Patent number: 10842879Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: GrantFiled: September 16, 2016Date of Patent: November 24, 2020Assignee: UNIVERSITY OF MIYAZAKIInventors: Kazuo Kitamura, Motoo Yamasaki
-
Publication number: 20190380571Abstract: An ophthalmologic apparatus comprises a measurement optical system to acquire information of an eye to be examined, an image obtaining part to obtain an anterior ocular segment image of the eye on an optical axis of the measurement optical system, a display to display the obtained anterior ocular segment image, cameras to each capture an image of an anterior ocular segment of the eye from a different direction, a driving mechanism to move the measurement optical system in a vertical direction and a horizontal direction, and a controller. The controller acquires three-dimensional position information of the eye based on the images captured by the cameras and calculates moving amounts in the vertical and horizontal directions of the measurement optical system based on the acquired position information. The controller displays the anterior ocular segment image on the display while positioning the measurement optical system with the driving mechanism.Type: ApplicationFiled: June 11, 2019Publication date: December 19, 2019Inventor: Kazuo KITAMURA
-
Patent number: 10335455Abstract: An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.Type: GrantFiled: March 3, 2017Date of Patent: July 2, 2019Assignee: University of MiyazakiInventors: Kazuo Kitamura, Shinya Ashizuka, Haruhiko Inatsu, Toshihiro Kita
-
Publication number: 20180264123Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: September 16, 2016Publication date: September 20, 2018Applicant: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki
-
Publication number: 20180170991Abstract: There is provided a novel adrenomedullin derivative capable of sustainably acting for a longer period than natural adrenomedullin. The invention relates to a compound represented by formula (I): A-Ln-B (I), wherein A is a modifying group selected from the group consisting of a palmitoyl group and a polyethylene glycol group, L is a divalent linking group, n is an integer of 0 or 1, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is bound to the modifying group A or the linking group L via the N-terminal ammo group of the peptide moiety B, or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: March 20, 2015Publication date: June 21, 2018Inventors: Kazuo Kitamura, Johji KATO, Keishi KUBO, Kenji KUWASAKO, Shigeru KUBO, Kumiko KUMAGAYE
-
Patent number: 9977983Abstract: A processing for specifying a correspondence relationship of feature points between two sets of optical data can be highly precise and efficiently carried out. The correspondence relationship of the perpendicular edges is obtained based on the assumption that the object is a building, in the processing for integrating the three-dimensional model obtained from the point cloud position data and the three-dimensional model obtained from the stereophotographic image. In this case, one perpendicular edge is defined by the relative position relationship with the other perpendicular edge, and the correspondence relationship is high-precisely and rapidly searched.Type: GrantFiled: June 20, 2013Date of Patent: May 22, 2018Assignee: KABUSHIKI KAISHA TOPCONInventors: Nobuo Kochi, Kazuo Kitamura
-
Publication number: 20170182126Abstract: An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.Type: ApplicationFiled: March 3, 2017Publication date: June 29, 2017Applicant: University of MiyazakiInventors: Kazuo Kitamura, Shinya Ashizuka, Haruhiko Inatsu, Toshihiro Kita
-
Patent number: 9629895Abstract: An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.Type: GrantFiled: January 12, 2012Date of Patent: April 25, 2017Assignee: University of MiyazakiInventors: Kazuo Kitamura, Shinya Ashizuka, Haruhiko Inatsu, Toshihiro Kita
-
Patent number: 9358724Abstract: There is provided a method for producing a chamber frame for a dialyzer, which is readily produced, has a stable quality, is inexpensive and is excellent in sealing property and heat resistance. A cut frame 1 is set on an unshown table of an impulse welder 30, distributors 13 are fitted into communicating passage 9 and communicating passages 11, and a net 15 is positioned so as to cover a central opening 3. Welded portions A and B, and the welded portions C and D are subjected to impulse welding. Mounting of the net 15 as a spacer and mounting of the distributors 13 are carried out simultaneously by a single pressing operation. After that, the welded portions of the net are deburred, and correction work is performed on defects.Type: GrantFiled: April 25, 2014Date of Patent: June 7, 2016Assignee: AGC ENGINEERING CO., LTD.Inventors: Yukio Matsumura, Shuichi Ohkawa, Tadao Yuki, Kazumi Ohshima, Kouji Nobuta, Taigo Ohsawa, Kazuo Kitamura